Reuters logo
BRIEF-Aclaris Therapeutics announces publication of phase 2 trial data of A-101 for treatment of facial seborrheic keratosis
2017年9月19日 / 中午12点19分 / 1 个月内

BRIEF-Aclaris Therapeutics announces publication of phase 2 trial data of A-101 for treatment of facial seborrheic keratosis

Sept 19 (Reuters) - Aclaris Therapeutics Inc

* Aclaris Therapeutics announces publication of data from phase 2 clinical trial of A-101 topical solution for treatment of facial seborrheic keratosis

* Aclaris Therapeutics Inc - ‍ in trial, A-101 achieved statistical significance in clearing SK lesions on face in a dose-related fashion​

* Aclaris Therapeutics Inc - ‍ FDA’s Prescription Drug User Fee Act Action date for new drug application is December 24, 2017​

* Aclaris Therapeutics Inc - ‍ A-101 was well tolerated at both concentrations studied​

* Aclaris Therapeutics Inc - ‍there were no treatment-related adverse events among patients treated with A-101​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below